Journal
PATHOLOGY & ONCOLOGY RESEARCH
Volume 20, Issue 4, Pages 789-797Publisher
SPRINGER
DOI: 10.1007/s12253-014-9837-z
Keywords
Cancer stem cells; Glioma; Glioma stem cells; Metformin; Therapeutic targeting
Funding
- Rosalinde and Arthur Gilbert Foundation
- STOP CANCER
- California Institute for Regenerative Medicine (CIRM) [DR1-01421]
- European Union Hungary-Croatia IPA Cross-border Co-operation Programme [HUHR/1001/2.1.3/0007 CABCOS 2]
Ask authors/readers for more resources
Malignant gliomas are among the deadliest primary brain tumors. Despite multimodal therapy and advances in chemotherapy, imaging, surgical and radiation techniques, these tumors remain virtually incurable. Glioma stem cells may be responsible for resistance to traditional therapies and tumor recurrence. Therefore, elimination of glioma stem cells may be crucial for achieving therapeutic efficacy. Metformin, a small molecule drug widely used in the therapy of type 2 diabetes, has shown significant anti-tumor effects in patients with breast cancer and prostate cancer. Recent preclinical data suggest that metformin also has therapeutic effects against glioma. Here we review the markers and hallmarks of glioma stem cells, and the molecular mechanisms involved in therapeutic targeting of glioma stem cells by metformin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available